Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)

Agios Pharmaceuticals (AGIO) jumped more than 14% after the FDA accepted its supplemental New Drug Application for mitapivat in sickle cell disease, granting Priority Review with a decision deadline of November 1. The regulatory green light comes despite the drug missing its primary endpoint for reducing sickle cell pain crises in clinical trials.

The FDA's willingness to pursue the accelerated approval pathway signals confidence in the submitted data package, even with the missed primary outcome. Mitapivat is already approved for other indications, and the sickle cell indication would expand its addressable market. Traditional full approval, however, hinges on a confirmatory Phase 3 trial slated to begin next year.

The November 1 target date creates a defined catalyst window for traders, compressing the timeline for a binary regulatory outcome. Priority Review status cuts the standard FDA review period roughly in half, from ten months to six.